This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of faster-acting insulin aspart in subjects with Type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
33
Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
Novo Nordisk Investigational Site
Graz, Austria
Mean plasma glucose concentration
Time frame: From 0-6 hours after start of a standardised meal
Area under the serum insulin aspart concentration-time curve
Time frame: From 0 to 12 hours after trial product administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.